Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 11 of 11 for “"BRD9"”.

  1. BRD9 Inhibition Overcomes Epithelial to Mesenchymal Transition-Associated Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer

    … in H1975OR. Bromodomain containing protein 9 (BRD9) was among the set of significantly upregulated chromatin regulators and was selected for further investigation as a mediator of drug tolerance. Although BRD9 is known to control stemness and EMT, its role in promoting EMT-associated TKI …

    buffalo Repository record for BRD9 Inhibition Overcomes Epithelial to Mesenchymal Transition-Associated Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer (opens in a new tab)

  2. Development of chemical probes for non-BET bromodomains

    … biological roles.Firstly, the development of I-BRD9, the first selective cellular probe for Bromodomain Containing Protein 9 (Brd9) is presented. I-BRD9 was identified through iterative medicinal chemistry, starting from a potent but unselective amide. Structure-based design was used to guide …

    strathclyde Repository record for Development of chemical probes for non-BET bromodomains (opens in a new tab)

  3. Molecular mechanisms regulating the chromatin architecture and gene transcription in human diseases

    … enzymes), my colleague and I uncovered that BRD9 is a key chromatin regulator to orchestrate the self-renewal/stemness of pancreatic CSCs. Perturbation of BRD9 (chemical inhibitor I-BRD9 or genetic ablation) can block the self-renewal and spheroid formation of pancreatic CSCs. Single-cell …

    oxford Repository record for Molecular mechanisms regulating the chromatin architecture and gene transcription in human diseases (opens in a new tab)

  4. Identifying the mechanisms driving pancreatic ductal adenocarcinoma stem cell characteristics using single-cell RNA-sequencing

    … PCSCs, and to assess the effects of I-BRD9, an inhibitor of BRD9, a bromodomain-containing protein involved in chromatin remodelling upon the PCSCs, using two single-cell RNA-sequencing PDAC datasets. The results evidenced cell cycle abnormalities as crucial to cancer stemness in PDAC, …

    oxford Repository record for Identifying the mechanisms driving pancreatic ductal adenocarcinoma stem cell characteristics using single-cell RNA-sequencing (opens in a new tab)

  5. Discovery of epigenetic probes against the bromodomain family of proteins

    … agents. Optimisation of a lead compound against BRD9 resulted in the development of LP99, the first reported BRD7/9 probe, that was potent (BRD9 <em>K</em><sub>D</sub> 99 nM, BRD7 <em>K</em><sub>D</sub> 909 nM), selective amongst bromodomain proteins and active in cells. An enantioselective …

    oxford Repository record for Discovery of epigenetic probes against the bromodomain family of proteins (opens in a new tab)

  6. Developing small molecule inhibitors of bromodomain-histone interactions

    … development of small molecule inhibitors for the BRD9 bromodomain, which is a component of nucleosome remodelling complexes, and has been linked to lung and cervical cancers. </p> <p>The lead molecule was based on the triazole KAc mimic, which is a promiscuous bromodomain ligand. Using a rational …

    oxford Repository record for Developing small molecule inhibitors of bromodomain-histone interactions (opens in a new tab)

  7. Design and synthesis of small molecule chemical probes for bromodomain-containing proteins

    … indolizine bromodomain-containing protein 9 (BRD9) inhibitor was used as the starting point for the development of a BRD9/BRD7 chemical probe. Analogues were synthesised via [3+2] cycloadditions. An optimised compound was found to be highly potent (68 nM) and selective over BRD4(1) (34-fold). …

    oxford Repository record for Design and synthesis of small molecule chemical probes for bromodomain-containing proteins (opens in a new tab)

  8. Investigating the role of epigenetic therapy in chemotherapy-resistant triple-negative breast cancer

    … the synergistic interaction between EZH2 and BRD9/7 inhibitors that abrogates the growth and migration of paclitaxel- and eribulin-resistant TNBC. Mechanistically, we identified that whereas inhibition of type I PRMT triggers the immunogenic viral mimicry response through the induction of …

    toronto-retro Repository record for Investigating the role of epigenetic therapy in chemotherapy-resistant triple-negative breast cancer (opens in a new tab)

  9. Chemical probe development for bromodomain and PHD finger-containing transcription factor (BPTF) reader domains as anti-cancer therapy

    … top-off targets included the bromodomains of BRD9 and CECR2. In Chapter 3, I describe efforts targeting a structured water in the BPTF binding site to improve selectivity. I optimized competitive assays for rapid off-target quantification, that led to second generation inhibitor, BZ2, which …

    umn Repository record for Chemical probe development for bromodomain and PHD finger-containing transcription factor (BPTF) reader domains as anti-cancer therapy (opens in a new tab)

  10. Discovery and Characterization of Small Molecule Inhibitors of Bromodomains

    The epigenetic “reader” modules bromodomains (BRDs) exert their diverse cellular functions through the recognition of acetylated lysines on histones and other proteins. Small molecule inhibitors of bromodomains have emerged as a promising therapeutic strategy to treat atherosclerotic cardiovascular …

    usf Repository record for Discovery and Characterization of Small Molecule Inhibitors of Bromodomains (opens in a new tab)